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A genome-wide screen in human embryonic
stem cells reveals novel sites of allele-specific
histone modification associated with known
disease loci
James G D Prendergast1*, Pin Tong2, David C Hay3, Susan M Farrington1 and Colin A M Semple1
Abstract
Background: Chromatin structure at a given site can differ between chromosome copies in a cell, and such
imbalances in chromatin structure have been shown to be important in understanding the molecular mechanisms
controlling several disease loci. Human genetic variation, DNA methylation, and disease have been intensely
studied, uncovering many sites of allele-specific DNA methylation (ASM). However, little is known about the
genome-wide occurrence of sites of allele-specific histone modification (ASHM) and their relationship to human
disease. The aim of this study was to investigate the extent and characteristics of sites of ASHM in human
embryonic stem cells (hESCs).
Results: Using a statistically rigorous protocol, we investigated the genomic distribution of ASHM in hESCs, and
their relationship to sites of allele-specific expression (ASE) and DNA methylation. We found that, although they
were rare, sites of ASHM were substantially enriched at loci displaying ASE. Many were also found at known
imprinted regions, hence sites of ASHM are likely to be better markers of imprinted regions than sites of ASM. We
also found that sites of ASHM and ASE in hESCs colocalize at risk loci for developmental syndromes mediated by
deletions, providing insights into the etiology of these disorders.
Conclusion: These results demonstrate the potential importance of ASHM patterns in the interpretation of disease
loci, and the protocol described provides a basis for similar studies of ASHM in other cell types to further our
understanding of human disease susceptibility.
Background
In genome-wide studies of human chromatin, chromatin
states are often assumed to be the same on both copies of a
chromosome. However, an increasing number of studies
has shown that a surprising level of heterogeneity can in
fact exist between the chromatin states of different alleles.
A recent study of allele-specific methylation (ASM) of
DNA in various pluripotent and adult cell lines estimated
that 23 to 37% of heterozygous single-nucleotide poly-
morphisms (SNPs) displayed differing levels of methylation
between alleles, with most ASM sites attributable to
heterozygote polymorphisms disrupting the guanine nu-
cleotide in CpG motifs [1].
Although DNA methylation is the best-characterized
mechanism [2], it is not the only level of chromatin that
has been shown to exhibit genome-wide allele-specific
patterns in humans. For example, the nuclease DNaseI
has been shown to cleave at sites of open chromatin and
to preferentially target regulatory elements such as pro-
moters and enhancers. Investigation of allele-specific
patterns of DNaseI hypersensitivity has shown that 7%
of DNaseI sites display allelic imbalances in sensitivity
[3].
Despite the crucial roles of histone modifications in
various biological processes, there has been no system-
atic investigation to date of the extent of human ASHM
genome-wide. At present, only a handful of sites have
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been found in the human genome, where histone modi-
fications are preferentially or exclusively associated with
a specific SNP allele [4,5]. The sites discovered in mice,
in which allele-specific histone modification (ASHM)
has been studied more extensively, have generally been
found around known imprinted regions [6-9]. Although
ASHM is therefore known to occur at particular
imprinted loci in mammals, often in conjunction with
allele-specific DNA methylation [8,10], the degree to
which it is associated with imprinted loci genome-wide,
and the extent of the overlap between ASHM and ASM
across the human genome remains unknown. Similarly,
the relative effect of ASM and ASHM on gene-expression
patterns across the genome is poorly understood.
Allele-specific patterns of other forms of chromatin
are associated with various disorders such as diabetes
[11-13] and despite being poorly characterized to date,
patterns of ASHM are likely to be important in under-
standing the incidence and progression of various dis-
eases [14]. Histone modifications are associated with a
variety of biological processes, most notably the regulation
of gene expression, and patterns of histone modification
specific to the parent of origin of the corresponding
chromosome, have already been associated with disorders
such as Prader-Willi syndrome (PWS) [15]. More gener-
ally, if sites of ASHM are associated with the expression of
neighboring genes, it might be expected that such genes
would be unusually sensitive to further perturbations in
their function. For example, if an ASHM variant is asso-
ciated with a loss of expression of one allele of a gene, then
expression of this gene will be particularly susceptible to
disruption via mutations of the second allele.
The discovery of regions of allele-specific chromatin
structure is consequently important for the interpret-
ation of variants and their phenotypic effects in genome-
wide association studies (GWAS) [16,17]. The targeted
investigation of associations between disease and SNPs
at known imprinted regions has been shown to give
stronger SNP-disease associations when the chromatin
status of each allele is taken into account [18]. Outside
imprinted regions, the discovery of sites at which chro-
matin state is associated with a particular allele or haplo-
type will assist the interpretation of GWAS results, and
conceivably the detection of causal variants.
In this study, we performed the first systematic survey of
allele-specific patterns of histone-modification patterns in
the human genome, by exploiting the unparalleled, large
volume of chromatin, expression, and genotyping data
now available for a widely used human embryonic stem
cell (hESC) line. We documented the extent of ASHM
across 23 well-studied histone modifications in the H1 cell
line, and found that ASHM is present throughout the
human genome and is detectable outside known imprinted
regions. Furthermore, ASHM patterns seem to involve
several relatively common allelic imbalances, preferentially
involving certain modifications. Through the use of
matched DNA methylation data, we also investigated the
relationship between ASM and ASHM and their relative
enrichments around known imprinted loci, and identified
ASHM is more specific in detecting imprinted regions.
Both DNA methylation and histone-modification patterns
are known to be associated with altered gene expression,
but for the first time we quantified their relative contribu-
tion to sites of allele-specific gene expression. We com-
pared the locations of sites of ASHM identified in the H1
cell line to those found in the fetal lung fibroblast cell line,
IMR90, and finally, we investigated the colocalization of
sites of ASHM in embryonic stem cells and known disease
loci associated with human developmental disorders [19].
Results and discussion
Distinct allele-specific histone imbalances across the
human genome
To identify sites of allele-specific DNA modification and
expression in the H1 hESC line, the locations of hetero-
zygous polymorphisms were first identified. Although
H1 has previously been genotyped, providing the loca-
tion of 153,718 heterozygous SNPs [20], each individual
is expected to carry more than 1.6 million heterozygous
SNPs [21]. This H1 genotyping-array data was therefore
used in conjunction with HapMap [22] and 1000 gen-
omes [21] haplotypes to impute the locations of a fur-
ther 1,572,866 putative heterozygote sites (IMPUTE [23]
probability of being a heterozygote> 0.5). The resulting
set of imputed heterozygotes was likely to contain false
positives, and so all putative heterozygotes were vali-
dated using sequencing data (see Methods).
We successful aligned 1.4 billion reads from a variety
of H1 chromatin immunoprecipitation (ChIP)-sequen-
cing datasets [24,25] (corresponding to a total of 23 dif-
ferent histone modifications; see Additional file 1) to the
human reference genome. Known heterozygous sites, at
which two or more histone modifications displayed sig-
nificantly different proportions of reads carrying each al-
lele, were identified. To ensure that any imbalance
detected was not simply a result of a shift in nucleosome
positioning between alleles (which would lead to similar
patterns of allelic imbalances for all modifications at a
position), we considered only sites displaying evidence of
different spectrums of histone modifications on each al-
lele to be sites of ASHM (rather than making an assess-
ment of allelic imbalance for each modification in
isolation; Table 1). It should be noted that this is cur-
rently an unprecedented and unique dataset for the
comprehensive identification of ASHM, offering the first
impression of the frequency and patterns of this
phenomenon across the entire human genome.
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In total, 51 sites (see Additional file 2) displaying evi-
dence of ASHM with P< 1.0 × 10−7 remained after
stringent filtering (see Methods). Clustering these sites
according to their allelic imbalance for each modification
highlighted that there were at least six different patterns
of ASHM at these positions (Figure 1A). Some ASHM
sites seemed to be driven by imbalances on a single copy
of a chromosome, with the sites that formed cluster 5
displaying consistent evidence of ASHM for the
H3K9me3 marker (Table 1, Figure 1B);one allele at these
loci being preferentially associated with nucleosomes
carrying the H3K9me3 modification, with no modifica-
tion preferentially associated with the second allele.
However, sites at which different modifications are
favored on each allele were also identified. For example,
Table 1 Modifications displaying allelic imbalance in each
of the clusters shown in Figure 1A
Modifications preferentially associated with:
Cluster Allele A Allele B
1 H3K4me3 –
2 H3K4me3 H3K27me3
3 H3K27me3 –
4 H3K36me3 –
5 H3K9me3 –
6 H3K9me3 H3K36me3
-30 (Preferentially allele A)
-20
-10
0 (No allelic imbalance)
10 (Preferentially allele B)
A
B
(6)
(5)
(4)
(3)
(2)
(1)
Figure 1 Clustering of significant sites of allele-specific histone modification in the H1 cell line by patterns of allele-specific
modification. (A) All 51 significant sites clustered according to the allelic imbalance seen for each examined histone modification. The scale
corresponds to the squared correlation of the observed allelic imbalances for each modification (as measured by the log of the respective
binomial P-value) between corresponding pairs of sites. Sites showing the strongest evidence of being largely driven by H3K4me3 preferentially
on one allele and H3K9me3 on the other are highlighted by the blue box (chr4:89004339, chr4:89004397, chr4:89004505, chr7:23729054,
chr15:22751085). (B) Allelic imbalance for each histone modification at the sites forming cluster 5. Most modifications displayed no consistent
evidence of allelic imbalance at these positions; however, H3K9me3 reads were found to preferentially contain allele ‘A’ at these sites (for this plot
the allele chosen to be the ‘A’ allele at each site was the allele found more often in the H3K9me3 reads at each position).
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sites in cluster 2 generally carry H3K27me3-modified (a
marker of transcriptional repression) nucleosomes on
one allele and H3K4me3-modified (associated with tran-
scriptionally active regions) nucleosomes on the other.
Although the ability to detect certain patterns of allelic
imbalances will depend on the coverage of the different
modifications in this study, these results highlight that a
spectrum of different forms of ASHM are present in the
human genome.
Allele-specific histone modifications are preferentially
linked to sites of allele-specific expression
Of the various biological processes associated with histone
modifications, the best characterized is the association of
these modifications with regulation of gene expression.
For example, the H3K27me3 modification has been asso-
ciated with repression and the H3K4me3 marker with ac-
tivation of gene expression [26], and therefore it is likely
that allele-specific modification patterns such as those we
found in cluster 2 (Table 1) may be reflected in the expres-
sion patterns of nearby genes. To investigate the potential
effect of ASHM on gene expression, we combined various
RNA-sequencing datasets derived from the H1 cell line,
and analyzed them for evidence of ASE at genes in close
proximity to the sites of ASHM. There was clear evidence
of the colocalization of both ASHM and gene expression
at many locations in the genome (Figure 2). In total, 19.6%
of ASHM sites were within 10 kb of a heterozygote site
displaying evidence of ASE (see Additional file 3), com-
pared with 4% of all high-coverage (>35x: the minimum
coverage of the 51 sites of ASHM; see Methods) heterozy-
gote sites (P= 1.2 × 10−7, χ² test). There was also some evi-
dence for enrichment of allele-specific PolII (ASP) sites
around locations of ASHM, with five sites of ASHM being
within 10 kb of a site of allele-specific PolII binding (see
Additional file 3); 9.8% of sites of ASHM versus 0.17% of
all high-coverage sites were within the same distance of a
location of ASP (P=3.4 × 10−8, Fisher’s exact test). Given
that many genes did not contain heterozygous sites or
possess sufficient RNA-sequencing coverage for ASE to be
determined, it is likely that even more ASHM sites than
could be detected in this study are in fact in close proxim-
ity to genes displaying allele-specific expression. In
addition, it is possible that some ASHM sites affect chro-
matin compaction and long-range interactions, with
delayed or more subtle effects on transcription, as has
been seen for asthma-associated variants conferring allele-
specific chromatin states [27].
Sites of allele-specific histone modification are more
enriched at imprinted regions than are sites of allele-specific
methylation
Patterns of allele-specific inactivation of gene expres-
sion can sometimes occur, through a process known
as imprinting. The imprinting of regions, by which
maternal and paternal copies of a gene display differ-
ent expression levels, has largely been attributed to
altered DNA methylation states, with ASM of nearby
CpG islands leading to different levels of gene ex-
pression from maternally and paternally derived
chromosomes [29]. However, there is growing evi-
dence from targeted studies that sites of ASHM may
also be acting to modulate the levels of methylation
at a locus [30]. To test whether ASHM was prefer-
entially associated with imprinted regions, we com-
pared their positions with the locations of known
imprinted genes from the Imprinted Gene Catalogue
[31]. A number of the ASHM loci were found to be in
close proximity to regions previously shown to be
imprinted, with 9 (17.6%) of the 51 most significant ASHM
sites being within 10 kb of a known imprinted gene (corre-
sponding to 5 distinct imprinted loci; see Additional file 3).
Given that only 0.6% of all high-coverage sites were within
10 kb of a known imprinted locus, this is a substantial
(29.3-fold), and highly significant enrichment of ASHM
sites around imprinted regions (P< 2.2 × 10−16, χ² test).
This observation is consistent with studies of mouse em-
bryonic fibroblasts, which also found ASHM to be asso-
ciated with imprinted regions [7,8]. Although many sites of
histone-modification imbalances between chromosomes at
imprinted regions probably do not overlap a heterozygote
SNP and so would not be detected as ASHM, these results
illustrate that ASHM is substantially enriched around
imprinted regions.
This result suggests that the location of ASHM could be
used to prioritize regions that are potentially imprinted.
The most significant site of ASHM detected in our study
mapped to the well-characterized imprinted locus on
15q11-13. In total, four sites of ASHM were detected in this
region, at two of which H3K9me3 was preferentially asso-
ciated with one chromosome at this locus, and H3K4me3
preferentially associated with the other (Figure 3). This is
consistent with previous studies in the mouse, which have
shown that overlapping sites of H3K4me3 and H3K9me3
are strongly associated with imprinting control regions [32].
Interestingly, the third, fifth, and sixth most significant
sites of ASHM (all mapping to the same locus on chromo-
some 4) also showed similar evidence of H3K4me3 on one
allele and H3K9me3 on the other, and clustered with one
of the sites of ASHM at the imprinted region on chromo-
some 15 (Figure 1A). Although, as far as we are aware, this
region is not currently known to be imprinted, the location
also displayed allele-specific PolII binding in close proxim-
ity, as also observed at the chromosome 15 imprinted
locus. This region is consequently a strong candidate for
follow-up studies investigating potential imprinting at this
locus. Imprinting at this locus would be particularly inter-
esting, given that variants in this region have previously
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been associated with bone-mineral density in GWAS [33],
suggesting that taking into account the parent of origin of
alleles at this locus might increase the strength of the
observed associations [18].
Although it is not possible to determine whether ASHM
is controlling the imprinting at known imprinted loci, or
whether it is simply a consequence, the enrichment of
ASHM around known imprinted loci is substantial. To
compare this enrichment to the extent of enrichment of
ASM at imprinted loci, we aligned Bisulfite sequencing
reads derived from the H1 cell line [34] to the reference
genome using the software Bismark [35]. Sites of ASM
were identified in a strand-specific manner by identifying
allelic imbalances at base positions of at least partial methy-
lation. Examination of the distribution of these ASM sites
in the genome highlighted that, as reported by other studies
[1], an overwhelming majority were adjacent to polymorph-
isms, as most allele-specific methylation sites are a result of
the guanine at CpG sites being polymorphic, leading to the
disruption of the CpG dinucleotide. Using our strict,
Figure 2 Patterns of allele-specific expression (ASE), histone modification (ASHM), and methylation (ASM) along chromosomes 15
(right) and 17 (left). Sites of ASE are plotted in the outer blue circle, ASHM in the middle red circle, and ASM in the inner green plot. Significant
sites are shaded darker in each case. Points correspond to –log(P) values in each plot except for ASM sites on the negative reference strand,
where log(P) is plotted (purple points in the inner green plot). Known imprinted loci and indel regions associated with developmental disorders
are indicated by orange and blue boxes, respectively, at the centre of the plot. Names of regions associated with developmental disorders within
250 kb of a site of ASHM are shown in red along with positions (in Mb) around the outside of the figure [28].
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Bonferroni-corrected P-value threshold of 1 × 10−8, only 38
out of the 7,569 significant sites of ASM were not located
directly adjacent to polymorphisms in the H1 cell line, with
an imputed heterozygote probability of greater or equal to
0.5. It is possible that at least some of the remaining 38
SNPs are also adjacent to unidentified polymorphisms.
Consequently, at least in this cell line, sites of strong ASM
are almost exclusively attributable to neighboring SNPs. Of
the 7,569 sites displaying significant evidence of ASM, only
0.24% were within 10 kb of an imprinted locus (18 sites
within 10 kb of 13 distinct imprinted loci), 73 times less
than the proportion of ASHM sites within the same dis-
tance of an imprinted region (P< 2.2 × 10−16, χ² test).
Examining the proportion of these ASM sites within 10 kb
of a known site of ASE showed that only 1.84% of sites
were within this distance, which is also significantly lower
than the proportion of ASHM sites (19.6%, as discussed
above, P< 2.2 × 10−16, χ² test).
Only two known imprinted regions displayed signifi-
cant evidence of both ASM and ASHM in this analysis:
the region around the GNAS1 gene on chromosome 20
and the imprinted locus on 15q11-13. Whereas many
sites of ASM are found all along chromosome 15, no
sites of significant ASHM are found on this chromo-
some outside this known imprinted locus. These results
show that, at least in hESCs, sites of ASHM are better
than sites of ASM as markers of imprinted regions, and
that ASHM is consequently likely to be more useful in
any search for novel imprinted loci.
Allele-specific histone modifications are enriched at
disease-causing micro-indel regions
Regions of allele-specific chromatin and gene inactiva-
tion are likely to be particularly susceptible to functional
perturbations following deletions. Deletion of a single
functional allele at such regions is more likely to be dele-
terious than a similar single deletion where two copies
of a region are functional and one remains after the de-
letion event. We therefore examined whether sites of
ASHM were located in close proximity to loci at which
deletions have been implicated in the onset of develop-
mental disorders [36]. We focused on developmental dis-
orders because of the likely importance of embryonic
stem cells in their progression. In total, nine sites of
ASHM (17.6%) were found to be within 250 kb of four
distinct regions known to be deleted in a developmental
disease or syndrome (see Additional file 3), corresponding
to a modest but significant enrichment over the propor-
tion of all high-coverage sites within the same distance
(6.7% of background sites, P=0.004, χ² test; significant
enrichments were also seen at 500 kb and 1 Mb). To fur-
ther narrow this list to the strongest candidates at which
ASHM is likely to be associated with a disease state, we
sought examples of those loci for which there was also
Figure 3 Allele ratio of the six histone modifications displaying the highest total coverage at four phased heterozygote sites at the
Prader-Willi locus. Sites without a corresponding bar had no reads for the corresponding histone-modification map to that position. The 95%
confidence intervals of the allele ratios are shown.
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evidence for allele-specific expression within close prox-
imity (site of ASE with P< 1 × 10−7 within 10 kb). After
this further filtering, seven sites remained; five at the
known imprinted region on chromosome 15q11-13, and
two at a second region located on 17q21.31.
The 15q11-13 region is a well-characterized imprinted
locus, and imprinting at this region has been shown to
be associated with a variety of disorders including PWS,
Angelman syndrome (AS), and autism spectrum disor-
ders [37,38]. This region displays clear evidence of
ASHM, ASE, and ASM (Figure 2). Detection of ASHM
at this locus is reassuring, being one of the few previ-
ously known locations of ASHM. ASHM at this locus is
largely driven by enrichment of the H3K9me3 histone
modification, a marker of transcriptional repression,
along a single haplotype (Figure 3).
The region at 17q21.31 has previously been shown to
contain two haplotypes, H1 and H2 (the latter inverted
relative to H1), and our analysis of haplotype marking var-
iants showed that the H1 cell line is heterozygous for
these haplotypes. One of the key genes in this region is
microtubule-associated protein tau (MAPT), which is
known to encode the protein that forms neurofibrillary
tangles in the brains of people with Alzheimer’s disease
[39]. A number of studies have found associations be-
tween the H1 haplotype and neurodegenerative disorders
such as Parkinson’s disease [39], and therefore it has been
assumed that MAPT underlies these disorders. Although
not expressed in embryonic stem cells, MAPT has previ-
ously been shown to be preferentially expressed from the
H1 haplotype, although the mechanism behind this is un-
known [40]. This region shows copy number variation in
some Europeans (see Methods); however, the SNPs we
used for analysis in this region could be unambiguously
phased with the haplotype marking variants, and we also
found further genes flanking MAPT to be preferentially
expressed from the H1 haplotype. Our analysis of the
ASHM sites at this locus (17:41700635 and 17:41700765)
showed that the H1 haplotype is preferentially associated
with the H3K4me3 histone modification linked with gene
activation, whereas the H2 haplotype is preferentially asso-
ciated with the repressive H3K27me3 marker, suggesting
that there is an association between the haplotype-specific
patterns of ASHM at this locus and the observed patterns
of ASE.
The presence of ASHM at these two disease loci is un-
likely to be due to chance; of all the sites of high ChIP
sequencing coverage in our dataset, only 0.5% (95% con-
fidence interval 0.45 to 0.57%) were within close proxim-
ity to a locus showing ASE that is also a known locus of
microindels leading to disease. Therefore, assuming in-
dependence between sites of ASHM and disease-causing
microindels, of the 51 sites displaying evidence of
ASHM, we would expect at most one of these to be in
close proximity of such a locus by chance. However, of
the sites displaying evidence of ASHM, seven sites
(13.7%) were in fact in close proximity to such regions
(27.4-fold enrichment; P< 2.2 × 10−16, χ² test) and all of
these sites were either at the 15q11-13 or 17q21.31 loci.
We also found persuasive evidence of allele-specific
expression at a third locus showing both ASHM and
microdeletions associated with the onset of developmen-
tal disorders; however, the ASE P-value at this location
at 17q12 was slightly below our stringent cut-off point
(P= 3.8 × 10−6). Nevertheless, all 19 RNA sequencing
reads mapping to a directly genotyped SNP at this locus
specifically carried one allele, suggesting that only a lack
of sequencing depth led it to fail the strict ASE signifi-
cance cut-off. We found that the site of ASHM maps to
a putative regulatory region bound by a variety of tran-
scription factors, and that the ASE corresponds to an
unannotated, spliced transcript directly adjacent to this
locus (see Additional file 4). The H3K27me3 repressive
marker is strongly associated with one allele at this
locus, with the active H3K36me3 modification to a lesser
extent preferentially associated with the second, support-
ing the hypothesis that this site of ASHM is potentially
associated with the observed ASE.
Overlap of allele-specific histone modification between
cell types
If the enrichment at sites of ASHM around loci known
to be deleted in developmental disorders is indeed spe-
cific to the H1 cell line as a result of its importance in
development, we would not expect to see a similar en-
richment in a differentiated cell line; however, if this en-
richment was an artifact of these regions being present
in variable copies in the human genome, we would ex-
pect to see such enrichments.
Thus, we applied our protocol to a second, fetal lung
fibroblast-derived cell line (IMR90), and found 16 sites
of ASHM (see Additional file 2), of which none were
within 250 kb of a locus known to be deleted in a devel-
opmental disease or syndrome (as opposed to the 9/51
sites in the H1 cell line). This tentatively supports our
hypothesis that the sites of ASHM identified in the H1
embryonic stem cell line are indeed specifically asso-
ciated with these regions; however, because of the small
number of ASHM sites seen in IMR90, additional data
and further analysis are required.
None of the 16 sites of ASHM detected in the IMR90
cell line was present in the H1 cell line. Only a subset of
relevant heterozygote sites were though present in both
datasets, and the sequencing coverage differed between
the cell lines for each modification and at different posi-
tions in the genome. Closer examination of the results
from both cell lines did not provide any evidence that
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there was a substantial enrichment of sites of ASHM in
the two cell lines located in close proximity. However, it
cannot be excluded that there were some sites of ASHM
present in both samples, but that there was insufficient
power to detect them in one or both datasets. For ex-
ample, the nearest heterozygote site in the IMR90 data-
set to the sites of ASHM in the H1 cell line (Figure 3)
had a suggestive ASHM P value of 4.7 × 10−4. This
P-value is largely attributable to the preferential associ-
ation of the H3K9me3 histone marker with one allele at
this locus, as also observed in the H1 cell line. It is
therefore likely that similar ASHM is present in both cell
lines at this locus, but there is insufficient coverage of
this region in the IMR90 cell line to obtain a P-value
below the strict threshold for genome-wide significance
we used in this study.
Conclusion
To date, there has been little investigation of the extent
and nature of ASHM across the human genome. In this
study, we undertook a comprehensive, genome-wide in-
vestigation of ASHM in an hESC line. Of more than 1.7
million putative heterozygote sites identified in this
study, more than 81,000 displayed high ChIP-sequencing
coverage (35x or more, see Methods), of which 51 dis-
played significant evidence of different allele ratios in
the reads from two or more histone-modification data-
sets. The results in this study therefore highlight that al-
though sites of ASHM are found throughout the
genome, they are probably not common. Owing to this
being the first genome-wide analysis of ASHM in
humans, a relatively stringent approach was used in this
study, which probably resulted in a higher false-negative
rate. However, the data used were combined from two
large international sequencing projects, so although the
generation of more data and for more modifications
would probably identify further sites, we can still state
that ASHM does not seem to be widespread, at least in
hESCs. In yeast, it has been shown that single base
changes can lead to predictable changes in nucleosome
positioning [41]; however, the results from the current
study argue against SNPs having a substantial wide-
spread effect on the modifications each nucleosome car-
ries. Changes in the underlying DNA are rarely associated
with changes in the modification carried by any overlying
nucleosome. This is in broad agreement with a recent study
that could find no evidence for selection acting on particu-
lar base changes at DNA underlying nucleosomes carrying
different histone modifications [42]. The fact that there is
little evidence that underlying DNA has a substantial affect
on histone modifications is perhaps unsurprising; patterns
and distributions of histone modifications vary between cell
types even when from the same genetic background. His-
tone modifications do not seem to be strongly reliant on
the DNA sequences immediately underlying the nucleo-
somes on which they occur. These data are in contrast to
the results we obtained when investigating ASM, which
was found to be relatively common and closely associated
with the underlying DNA, with almost all sites of ASM
identified being attributable to a neighboring SNP. These
results would suggest there are probably different mechan-
isms controlling ASHM and ASM in embryonic stem cells,
and that one does not necessarily lead to the other.
We have shown in this study that despite sites of
ASHM not being widespread, they are likely to be im-
portant. ASHM sites were found to be enriched around
genes displaying evidence of ASE. Although this is not
evidence of a direct link, it is likely, given the known
role of histone modifications in gene expression, that at
least some of these sites of ASHM are directly associated
with allele-specific gene expression. ASM, which is
already known to be directly associated with allele-specific
gene expression, was substantially less enriched around
sites of ASE. Consequently, the few sites of ASHM identi-
fied in this study would seem to be having a disproportion-
ate affect on gene expression.
Sites of ASHM were also substantially more enriched
around known imprinted genes than sites of ASM. We
found that 1 in 6 sites of ASHM were within 10 kb of a
known imprinted locus, as opposed to 1 in 417 sites of
ASM. This suggests that ASHM is a substantially stronger
marker of imprinted genes in embryonic stem cells than is
ASM, and will probably be more informative in any
searches for novel imprinted loci. It would seem that the
reason that sites of ASM display such limited enrichment
around imprinted regions is because the most significant
sites are overwhelmingly the result of adjacent polymorph-
isms. This result also suggests that strong epialleles (DNA
methylation differences between alleles that are not attrib-
utable to underlying DNA polymorphisms) are likely to be
relatively rare in hESCs. The lack of strong enrichment of
sites of ASM around imprinted regions may also be partly a
result of imprinted regions having smaller differences in
methylation between chromosomes across longer stretches,
compared with sites at which CpG motifs are disrupted by
a heterozygous SNP. Smaller differences in methylation
levels will be difficult to detect without extremely high
coverage, when robustly accounting for the substantial
number of sites tested genome-wide.
Interestingly, despite the highly significant enrichment
of ASHM sites around known imprinted regions, most
ASHM sites were not associated with such regions. This
suggests that either there are a substantial number of
imprinted regions yet to be defined in the human gen-
ome or that ASHM is often located distinct from
imprinted loci.
Analysis of the distribution of ASHM sites relative to
the position of known microdeletion syndrome loci led
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to the discovery that one in six sites of allele-specific his-
tone modification were within 250 kb of a locus at which
deletions have been associated with developmental dis-
orders. The observation of sites of ASHM at the PWS
genomic interval on 15q11-13 is in agreement with pre-
vious studies [43]. Targeted studies in mice looking at
the patterns of histone modification at this imprinted
locus in murine embryonic brain samples have identified
enrichment of H3K4me2 and H3Ac modifications along
the paternal chromosome, with H4K20me3-, H3K36me3-,
H3K9me3-, and H3K79me3-modified nucleosomes
enriched along the silenced maternal copy [43]. Our ob-
servation of preferential enrichment of the H3K9me3 mar-
ker along the same phased haplotype in this study is
therefore in broad agreement with the observed parent-of-
origin chromosome bias of this modification in mice.
However, the observed bias of the H3K36me3 histone
modification along the silenced maternal chromosome in
the same mouse study was more surprising, given that this
histone mark has previously been associated with active,
transcribed regions [44]. In the current study looking at
hESCs, we found sites in this region preferentially covered
by nucleosomes carrying H3K36me3 were located on both
chromosomes, suggesting that this modification is not
preferentially associated with either chromosome copy in
hESCs. This observation of sites of H3K36me3 on both
the silenced and active copies of this region in humans is
in agreement with the broader observation that this mar-
ker is found at both transcriptionally active and repressed
regions in mice, including mouse embryonic stem cells
[43].
Although rare, ASHM is consequently likely to play an
important role in human development. The location of
sites of ASHM at key imprinted and ASE loci and at sites
associated with developmental disorders suggests that
ASHM is an important but as yet undercharacterized
phenomenon involved in embryonic development.
Methods
Heterozygote SNP imputation analysis
The genotypes at 480,621 SNP positions in the H1 cell
line were obtained from the report of Mosher et al. [20],
and used in conjunction with the IMPUTE program [23]
to determine the putative positions of heterozygote
SNPs and haplotypes in this cell line. Imputation was
carried out using the combined HapMap 3 (release 2)
and 1000 Genomes pilot CEU (Utah residents with
Northern and Western European ancestry) haplotypes
available at the IMPUTE website (H1 has previously
been shown to be of European origin [20]). All SNPs
present on the genotyping array were given a predicted
probability of 1 for the corresponding genotype. In total,
1,728,322 positions had a predicted probability of greater
than or equal to 0.5 of being a heterozygote, that is, were
more likely to be a heterozygote than a homozygote. This
number is in broad agreement with the expected number
of heterozygote sites in an individual [21]. However, as this
set of polymorphic sites was likely to contain a large num-
ber of false positives, all of these putative heterozygotes
were also validated using whole-genome Bisulfite sequen-
cing data as detailed below.
Detection of allele-specific DNA methylation
Bisulfite sequencing reads were mapped to the hg18 ver-
sion of the human reference genome using the Bismark
software [35]. Seven libraries were excluded from subse-
quent analysis because they gave substantially different
estimates of the number of methylated sites in the H1
genome than the other 200 libraries (see Additional file
5 for more details). In total, the mean coverage of
mapped reads across both strands was 32x. The reads
carrying each allele at each imputed heterozygote site
was determined for reads mapping to the forward and
reverse strand independently (sites of C/T polymorph-
isms on the respective strand were excluded).
Analysis of the Bisulfite sequencing data showed that it
could successfully be used to confidently identify hetero-
zygote sites in the H1 cell line. Filtering positions accord-
ing to known sites of polymorphisms in the 1000 Genome
and HapMap datasets, and with at least two reads being
present in the Bisulfite sequencing data carrying each
known allele, allowed us to capture heterozygote sites with
a very low false-positive rate. Comparison of these SNP
calls to the genotyping-array data highlighted that the sen-
sitivity and specificity of detecting heterozygotes using this
approach were 78.5% and 99.7% respectively (positive pre-
dictive value of 99.2%), that is, the false-positive rate was
0.3%. Consequently, this Bisulfite sequencing data was
used to further filter the putative heterozygote sites identi-
fied in the imputation analysis. Only sites with a heterozy-
gote probability of ≥0.5 from the imputation analysis, and
with at least two reads for each of the two respective
alleles seen at the corresponding position in the Bisulfite
sequencing data, were retained for downstream analyses
(including the identification of ASHM). This approach
ensured that the false-positive rate in this study was as
low as possible. After this filtering, 1,230,096 heterozygote
sites were left. In the absence of genotyping data for
IMR90, we also used the Bisulfite sequencing data to iden-
tify putative heterozygote sites as described.
To detect sites of ASM, the methylation status at each
position along each mapped Bisulfite sequencing read was
determined (excluding known polymorphic positions in the
1000 Genomes and HapMap data from IMPUTE), and the
total number of reads displaying evidence of methylation at
a position and carrying a given allele at the respective het-
erozygote site was calculated. Bases with Phred-scaled qual-
ities of less than 13 were excluded from these calculations.
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The proportions of methylated and unmethylated bases at
a given position were then compared between groups of
reads carrying each allele at the corresponding heterozygote
site using a Fisher’s exact test. The cut-off for significance
in this analysis was set to 1 × 10−8, which approximately
corresponds to a Bonferroni-corrected P-value of 0.05
(3,410,426 putative sites of ASM tested). It should be said
that a less stringent threshold could have potentially been
used, not least because by applying a Bonferroni correction,
we assumed that methylation levels at neighboring sites are
independent, but this is known not to be the case [1]. The
threshold used in this study can therefore be considered
robust.
Detection of allele-specific histone modifications
All sequence data used in this project were generated by
the ENCODE [24,45] or National Institute of Health
Roadmap Epigenomics [25] projects (for a full list of the
datasets used see Additional file 6). All ChIP-sequencing
reads were mapped to the hg18 build of the Human
Reference Genome, using the Bowtie short read aligner
with the ‘−best’ flag [46]. In total 1,389,697,934 reads
were successfully mapped (an average of 60.4 million per
histone modification; see Additional file 1). The numbers
of reads carrying each possible allele (with respect to the
positive strand) at all of the imputed heterozygous posi-
tions (after filtering using the Bisulfite sequencing data
as described above) were determined for each histone
modification. Low-quality read bases (Phred-scaled qual-
ity< 13) were ignored. A 4 × 23 contingency table was
constructed for each site, corresponding to the number
of reads for each allele and each modification. Having
removed columns and rows that summed to 0, this table
was used as the input of a Fisher’s exact test to identify
sites of ASHM (see Additional file 7 for further details
of this approach). A significance threshold of 1 × 10−7
was used in this analysis. Owing to the probably higher
false-positive rate in the previous 1000 genomes dataset,
sites not in the later (October 2011) 1000 Genomes re-
lease were ignored. Under conservative assumptions that
the mean power to detect sites of ASHM in this study
was on average around 0.1, and that only 0.001% of the
approximately 15 million nucleosomes expected to be
found along the human genome in fact display evidence
of ASHM, the posterior odds will be 10 to 1 in favor of
any site exceeding this threshold being a true association
[47].
This test identified sites at which the proportion of
reads carrying a particular allele was different between at
least two histone-modification datasets. Although the
imputation analysis and subsequent filtering according
to the Bisulfite sequencing data would probably have
produced a number of false-positive heterozygotes, this
approach meant that they could not be detected as sites
of ASHM. A putatively heterozygous position requires a
substantial difference in the proportions of reads carry-
ing each allele between datasets to be called as a location
of ASHM. At true homozygote positions, only one allele
will be identified (sequencing errors are not expected to
produce a sufficient number of alternative alleles to
reach significance, and should also occur at relatively
uniform rates between datasets). This approach also
ensured that the putative sites of ASHM were not in fact
a result of differences in nucleosome occupancy between
chromosomes. Such differences may lead to different
observed proportions of reads carrying each allele within
a particular modification dataset overlapping a site, but
should not change the proportion of reads carrying each
allele between modification datasets (see Additional file
7 for a fuller explanation of the method for calling sites
of ASHM).
Despite the resulting low SNP false-positive rate, it is
possible that differences between duplicated regions in
the human genome could be mistaken as heterozygote
polymorphisms. Although our approach of only identify-
ing sites at which the allele ratios are different between
at least two histone-modification datasets would exclude
many potential false positives arising from such duplica-
tion events (as duplication events in which the modifica-
tion state has stayed the same or has been completely
lost will not be detected as sites of ASHM), differences
between the histone-modification spectrums at dupli-
cated sites could potentially be erroneously called as
sites of ASHM. For example, although large (>3 to
400 kb) duplications are incredibly rare at the sites asso-
ciated with developmental delay used in this study [36],
smaller sections of the 17q21.31 region have previously
been shown to be duplicated in some Europeans, and to
have higher coverage in corresponding sequencing data-
sets [48]. To investigate whether duplication events
might underlie the ASHM sites identified in this study
we therefore first investigated whether there was evi-
dence of an excess of Bisulfite sequencing read depth at
these positions (the Bisulfite data being used because it
was untargeted whole-genome sequencing data). Sites of
duplications have been shown to lead to an increase in
coverage of the respective sites [48]; however, we found
that the mean coverage at the ASHM sites in this study
was is in fact lower than the mean coverage across the
whole genome (see Additional file 8), suggesting that as
a group they are not enriched with duplicated sites.
Using the 1000 Genomes CEU data release of October
2011, we also ensured all the SNPs underlying sites of
ASHM were in Hardy-Weinberg equilibrium (HWE),
because duplications and high-frequency copy number
variations (such as that at 17q21.31) would be expected
to cause false-positive SNPs to deviate from HWE [49].
Although the distribution of HWE values was similar
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for both the ASHM and all high-coverage sites (see
Additional file 8), suggesting that there is no system-
atic bias at ASHM sites towards SNPs out of HWE,
we excluded three sites whose HWE P-value was less
than 0.05. This is probably over-conservative, given
that we would in fact expect the same number of
SNPs to have a HWE P-value lower than this cut-off
value, purely by chance. The same filtering was ap-
plied to the IMR90 sites of ASHM. None was out of
HWE, and there was no substantial systematic bias in
read-depth coverage. Therefore, although it is not
possible to say unequivocally that every ASHM site
identified in this study has only two copies in these
cell lines, there is no evidence that the ASHM sites
identified are, as a group, false positives resulting
from duplication events.
In order to allow clustering of sites displaying signifi-
cant evidence of ASHM by their histone-modification
patterns, we calculated the degree of allelic imbalance
for each individual modification at each site using a bi-
nomial test. Each of the resulting P-values for each
modification at each site were then log-transformed, and
sites clustered by their squared Pearson’s correlation co-
efficient using the R statistical package [50]. The six
clusters were identified by defining a cut-off point in the
dendrogram shown in Figure 1A. This cut-off point was
chosen by progressively lowering the cut-off until further
lowering it resulted in multiple clusters driven primarily
by the same modification(s). The modifications driving
each cluster were identified by determining those modi-
fications with small binomial P-values across all of the
sites in the cluster.
To investigate the enrichment of ASHM in and
around various annotations, sites of significant ASHM
were compared only to those heterozygote sites with
high ChIP-sequencing coverage; that is, only those het-
erozygote sites identified using the imputation and Bisul-
fite sequencing data that were covered by at least 35
ChIP-sequencing reads (with only sites in the October
2011 1000 Genome release being again retained). A read
number of 35 was chosen as the cut-off point as this
was the minimum number of reads identified at the 51
sites of ASHM. Comparing sites of ASHM with the
81,029 such sites of high ChIP-sequencing read depth,
rather than with all heterozygote positions, consequently
ensured that any enrichment at ASHM sites was mea-
sured relative to all heterozygote positions covered by
modified nucleosomes and at which ASHM was poten-
tially detectable if it existed. The locations of 71 human
imprinted loci were obtained from the study of Morrison
et al. [31] (the PWS/AS locus was treated as one distinct
region in this analysis). Sites of deletions associated with
developmental delay were obtained from the data of
Cooper et al. [36]. SNPs were phased using IMPUTE in
conjunction with the 1000 Genomes CEU haplotypes
[21].
Detection of allele-specific expression and PolII binding
All RNA-sequencing and PolII ChIP-sequencing reads
were initially mapped using Bowtie with the ‘–best’ flag
[46]. For details of the datasets used see Additional file
6. Those RNA-sequencing reads that were unmapped by
Bowtie were then run through the spliced-read mapper
TopHat [51]. Sites of ASE and PolII binding were called
by determining the number of reads at each heterozy-
gote site carrying each allele, and deviations from the
expected 50/50 ratio were assessed using a binomial test.
Reads in which the base at the heterozygote site had a
Phred-scaled quality of less than 13 were excluded from
this analysis. Owing to the high sensitivity for heterozy-
gote false positives in this analysis (all such false posi-
tives would probably be called as highly significant sites
of ASE) we used the Bisulfite sequencing data to
minimize the false positive rate as previously described,
that is, only SNP genotyping-array heterozygote SNPs or
imputed sites with a heterozygote probability greater
than 0.5 and at least two Bisulfite sequencing reads car-
rying each allele were kept. A P-value threshold of 1 ×
10−7 was used in this analysis.
Haplotype analysis
SNPs were phased using IMPUTE in conjunction with
the 1000 Genome CEU haplotypes. In total, 19 inver-
sion-marking SNPs with a dbSNP rs ID taken from the
study of Donnelly et al. [52] were used to determine
which phased haplotype was H1 and which H2 at the
17q21.31 locus (although there are 21 inversion-marking
SNPs listed in this paper, 1 did not have an rs ID so was
not imputed, and the listed alleles for another did not
match those found in the 1000 Genomes data, and was
therefore excluded). All 19 SNPs agreed in the discrim-
ination of the H1 and H2 haplotypes.
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Abbreviations
AS: Angelman syndrome; ASHM: Allele-specific histone modification;
ASM: Allele-specific methylation; ASE: Allele-specific expression;
ChIP: Chromatin immunoprecipitation; GWAS: Genome-wide association
studies; hESC: Human embryonic stem cell; HWE: Hardy-Weinberg
equilibrium; PWS: Prader-Willi syndrome; SNP: Single-nucleotide
polymorphism.
Competing interests
The author(s) declare that they have no competing interests.
Acknowledgements
We are very grateful to Noah Rosenberg (University of Michigan) for
providing the H1 genotyping data and for the assistance and helpful
comments of Brendan Loftus, Wendy Bickmore and Andrew Wood. We
would also like to acknowledge the ENCODE and NIH Roadmap
Epigenomics Projects for making their datasets freely available for public use.
We would finally like to thank three anonymous reviewers for their helpful
comments and suggestions. This work was supported by the UK Medical
Research Council [JGDP and CAM]; RCUK [DCH]; Chief Scientist Office [CZB/4/
449 to SMF] and Science Foundation Ireland [PT].
Author details
1MRC Human Genetics Unit, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Western General Hospital, Crewe Road, ,
EdinburghEH4 2XU, UK. 2UCD Conway Institute for Biomolecular and
Biomedical Research, Dublin, Ireland. 3MRC Centre for Regenerative Medicine,
University of Edinburgh, 49 Little France Crescent, EdinburghEH16 4SB, UK.
Authors’ contributions
JGDP and CAMS conceived of the study and drafted the initial manuscript.
JGDP and PT undertook the bioinformatic analysis. All authors contributed to
and approved the final manuscript.
Received: 23 January 2012 Accepted: 10 April 2012
Published: 19 May 2012
References
1. Shoemaker R, Deng J, Wang W, Zhang K: Allele-specific methylation is
prevalent and is contributed by CpG-SNPs in the human genome.
Genome Res 2010, 20:883–889.
2. Tycko B: Allele-specific DNA methylation: beyond imprinting. Hum Mol
Genet 2010, 19:R210–R220.
3. McDaniell R, Lee B-K, Song L, Liu Z, Boyle AP, Erdos MR, Scott LJ, Morken
MA, Kucera KS, Battenhouse A, Keefe D, Collins FS, Willard HF, Lieb JD, Furey
TS, Crawford GE, Iyer VR, Birney E: Heritable individual-specific and
allele-specific chromatin signatures in humans. Science 2010,
328:235–239.
4. Kadota M, Yang HH, Hu N, Wang C, Hu Y, Taylor PR, Buetow KH, Lee MP:
Allele-specific chromatin immunoprecipitation studies show genetic
influence on chromatin state in human genome. PLoS Genet 2007, 3:e81.
5. Wen B, Wu H, Bjornsson H, Green RD, Irizarry R, Feinberg AP: Overlapping
euchromatin/heterochromatin- associated marks are enriched in
imprinted gene regions and predict allele-specific modification. Genome
Res 2008, 18:1806–1813.
6. Kim J-M, Ogura A: Changes in allele-specific association of histone
modifications at the imprinting control regions during mouse
preimplantation development. Genesis 2009, 47:611–616.
7. Singh P, Han L, Rivas GE, Lee D-H, Nicholson TB, Larson GP, Chen T, Szabó
PE: Allele-specific H3K79 Di- versus trimethylation distinguishes opposite
parental alleles at imprinted regions. Mol Cell Biol 2010, 30:2693–2707.
8. Singh P, Cho J, Tsai SY, Rivas GE, Larson GP, Szabó PE: Coordinated
allele-specific histone acetylation at the differentially methylated regions
of imprinted genes. Nucleic Acids Res 2010, 38:7974–7990.
9. Fournier C, Goto Y, Ballestar E, Delaval K, Hever AM, Esteller M, Feil R:
Allele-specific histone lysine methylation marks regulatory regions at
imprinted mouse genes. EMBO J 2002, 21:6560–6570.
10. Singh P, Wu X, Lee D-H, Li AX, Rauch TA, Pfeifer GP, Mann JR, Szabó PE:
Chromosome-wide analysis of parental allele-specific chromatin and
DNA methylation. Mol Cell Biol 2011, 31:1757–1770.
11. Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, Teschendorff AE, Akan
P, Stupka E, Down TA, Prokopenko I, Morison IM, Mill J, Pidsley R, Deloukas
P, Frayling TM, Hattersley AT, McCarthy MI, Beck S, Hitman GA: Integrated
genetic and epigenetic analysis identifies haplotype-specific methylation
in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One
2010, 5:e14040.
12. Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, Panhuis
TM, Mieczkowski P, Secchi A, Bosco D, Berney T, Montanya E, Mohlke KL,
Lieb JD, Ferrer J: A map of open chromatin in human pancreatic islets.
Nat Genet 2010, 42:255–259.
13. Verlaan DJ, Berlivet S, Hunninghake GM, Madore A-M, Larivière M,
Moussette S, Grundberg E, Kwan T, Ouimet M, Ge B, Hoberman R, Swiatek
M, Dias J, Lam KCL, Koka V, Harmsen E, Soto-Quiros M, Avila L, Celedón JC,
Weiss ST, Dewar K, Sinnett D, Laprise C, Raby BA, Pastinen T, Naumova AK:
Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3
locus associated with the risk of asthma and autoimmune disease. Am J
Hum Genet 2009, 85:377–393.
14. Bannister AJ, Kouzarides T: Regulation of chromatin by histone
modifications. Cell Res 2011, 21:381–395.
15. Xin Z, Allis CD, Wagstaff J: Parent-specific complementary patterns of
histone H3 lysine 9 and H3 lysine 4 methylation at the Prader-Willi
syndrome imprinting center. Am J Hum Genet 2001, 69:1389–1394.
16. Rakyan VK, Down TA, Balding DJ, Beck S: Epigenome-wide association
studies for common human diseases. Nat Rev Genet 2011, 12:529–541.
17. Birney E, Lieb JD, Furey TS, Crawford GE, Iyer VR: Allele-specific and
heritable chromatin signatures in humans. Hum Mol Genet 2010,
19:R204–R209.
18. Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher
S, Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML,
Gylfason A, Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson
B, Benediktsdottir KR, Sigurdsson H, Jonsson T, Benediktsson R, Olafsson JH,
Johannsson OT, Hreidarsson AB, Sigurdsson G, Ferguson-Smith AC,
Gudbjartsson DF, Thorsteinsdottir U, Stefansson K: Parental origin of
sequence variants associated with complex diseases. Nature 2009,
462:868–874.
19. Koolen DA, Vissers LELM, Pfundt R, De Leeuw N, Knight SJL, Regan R, Kooy
RF, Reyniers E, Romano C, Fichera M, Schinzel A, Baumer A, Anderlid B-M,
Schoumans J, Knoers NV, van Kessel AG, Sistermans EA, Veltman JA, Brunner
HG, de Vries BBA: A new chromosome 17q21.31 microdeletion syndrome
associated with a common inversion polymorphism. Nat Genet 2006,
38:999–1001.
20. Mosher JT, Pemberton TJ, Harter K, Wang C, Buzbas EO, Dvorak P, Simón C,
Morrison SJ, Rosenberg NA: Lack of population diversity in commonly
used human embryonic stem-cell lines. N Engl J Med 2010, 362:183–185.
21. The 1000 Genomes Project Consortium: A map of human genome
variation from population-scale sequencing. Nature 2010, 467:1061–1073.
22. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L,
Dermitzakis E, Schaffner SF, Yu F, Peltonen L, Dermitzakis E, Bonnen PE,
Altshuler DM, Gibbs RA, de Bakker PIW, Deloukas P, Gabriel SB, Gwilliam R,
Hunt S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker P, Yu F, Chang K,
Hawes A, Lewis LR, Ren Y, Wheeler D, Gibbs RA, Muzny DM, Barnes C,
Darvishi K, Hurles M, Korn JM, Kristiansson K, Lee C, McCarrol SA, Nemesh J,
Dermitzakis E, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N,
Bonnen PE, Gibbs RA, Gonzaga-Jauregui C, Keinan A, Price AL, Yu F, Anttila
V, Brodeur W, Daly MJ, Leslie S, McVean G, Moutsianas L, Nguyen H,
Schaffner SF, Zhang Q, Ghori MJR, McGinnis R, McLaren W, Pollack S, Price
AL, Schaffner SF, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, Sabeti
PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca MC, Marshall
PA, Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, Royal CD, Sharp RR,
Zeng C, Brooks LD, McEwen JE: Integrating common and rare genetic
variation in diverse human populations. Nature 2010, 467:52–58.
23. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet 2009, 5:e1000529.
Prendergast et al. Epigenetics & Chromatin 2012, 5:6 Page 12 of 13
http://www.epigeneticsandchromatin.com/content/5/1/6
24. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, Raney
BJ, Wang T, Hinrichs AS, Zweig AS, Fujita PA, Learned K, Rhead B, Smith KE,
Kuhn RM, Karolchik D, Haussler D, Kent WJ: ENCODE whole-genome data
in the UCSC Genome Browser. Nucleic Acids Res 2009, 38:D620–D625.
25. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A,
Meissner A, Kellis M, Marra MA, Beaudet AL, Ecker JR, Farnham PJ, Hirst M,
Lander ES, Mikkelsen TS, Thomson JA: The NIH roadmap epigenomics
mapping consortium. Nat Biotechnol 2010, 28:1045–1048.
26. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K,
Roh T-Y, Peng W, Zhang MQ, Zhao K: Combinatorial patterns of histone
acetylations and methylations in the human genome. Nat Genet 2008,
40:897–903.
27. Verlaan DJ, Berlivet S, Hunninghake GM, Madore A-M, Larivière M,
Moussette S, Grundberg E, Kwan T, Ouimet M, Ge B: Allele-specific
chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus associated
with the risk of asthma and autoimmune disease. Am J Hum Genet 2009,
85:377–393.
28. Krzywinski MI, Schein JE, Birol I, Connors J, Gascoyne R, Horsman D, Jones
SJ, Marra MA: Circos: an information aesthetic for comparative genomics.
Genome Res 2009, 19:1639–1645.
29. Ferguson-Smith AC: Genomic imprinting: the emergence of an epigenetic
paradigm. Nat Rev Genet 2011, 12:565–575.
30. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H,
Tempst P, Lin S-P, Allis CD, Cheng X, Bestor TH: DNMT3L connects
unmethylated lysine 4 of histone H3 to de novo methylation of DNA.
Nature 2007, 448:714–717.
31. Morison IM, Ramsay JP, Spencer HG: A census of mammalian imprinting.
Trends Genet 2005, 21:457–465.
32. Dindot SV, Person R, Strivens M, Garcia R, Beaudet AL: Epigenetic profiling
at mouse imprinted gene clusters reveals novel epigenetic and genetic
features at differentially methylated regions. Genome Res 2009,
19:1374–1383.
33. Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu Y-H, Richards
JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas
P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB,
Oostra B, Pastinen T, Pols HAP, Sigurdsson G, Soranzo N, Thorleifsson G,
Thorsteinsdottir U, Williams FMK, Wilson SG, Zhou Y, Ralston SH, van Duijn
CM, Spector T, Kiel DP, Stefansson K, Ioannidis JPA, Uitterlinden AG: Twenty
bone-mineral-density loci identified by large-scale meta-analysis of
genome-wide association studies. Nat Genet 2009, 41:1199–1206.
34. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery
JR, Lee L, Ye Z, Ngo Q-M, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti
V, Millar AH, Thomson JA, Ren B, Ecker JR: Human DNA methylomes at
base resolution show widespread epigenomic differences. Nature 2009,
462:315–322.
35. Krueger F, Andrews SR: Bismark: a flexible aligner and methylation caller
for Bisulfite-Seq applications. Bioinformatics 2011, 27:1571–1572.
36. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C,
Stalker H, Hamid R, Hannig V, Abdel-Hamid H, Bader P, McCracken E,
Niyazov D, Leppig K, Thiese H, Hummel M, Alexander N, Gorski J, Kussmann
J, Shashi V, Johnson K, Rehder C, Ballif BC, Shaffer LG, Eichler EE: A copy
number variation morbidity map of developmental delay. Nat Genet
2011, 43:838–46.
37. Boyle J, Hawkins M, Barton DE, Meaney K, Guitart M, O’Grady A, Tobi S,
Ramsden SC, Elles R, Gray E, Metcalfe P, Hawkins JR: Establishment of the
first WHO international genetic reference panel for Prader Willi and
Angelman syndromes. Eur J Hum Genet 2011, 19:857–864.
38. Schanen NC: Epigenetics of autism spectrum disorders. Hum Mol Genet
2006, 15(Spec No 2):R138–R150.
39. Pennisi E: 17q21.31: not your average genomic address. Science 2008,
322:842–845.
40. Kwok JBJ, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, Buchanan
DD, Silburn PA, Schofield PR: Tau haplotypes regulate transcription and
are associated with Parkinson’s disease. Ann Neurol 2004, 55:329–334.
41. Tirosh I, Sigal N, Barkai N: Divergence of nucleosome positioning between
two closely related yeast species: genetic basis and functional
consequences. Mol Syst Biol 2010, 6:365.
42. Prendergast J, Semple C: Widespread signatures of recent selection linked
to nucleosome positioning in the human lineage. Genome Res 2011,
21:1777–1787.
43. Chantalat S, Depaux A, Héry P, Barral S, Thuret J-Y, Dimitrov S, Gérard M:
Histone H3 trimethylation at lysine 36 is associated with constitutive
and facultative heterochromatin. Genome Res 2011, 21:1426–1437.
44. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, Wei G, Chepelev
I, Zhao K: High-resolution profiling of histone methylations in the human
genome. Cell 2007, 129:823–837.
45. Myers RM, Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC,
Bernstein BE, Gingeras TR, Kent WJ, Birney E, Wold B, Crawford GE: A user’s
guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011, 9:
e1001046.
46. Langmead B, Trapnell C, Pop M, Salzberg SL: Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome.
Genome Biol 2009, 10:R25.
47. The Wellcome Trust Case Control Consortium: Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared
controls. Nature 2007, 447:661–678.
48. Sudmant PH, Kitzman JO, Antonacci F, Alkan C, Malig M, Tsalenko A,
Sampas N, Bruhn L, Shendure J, 1000 Genomes Project, Eichler EE: Diversity
of human copy number variation and multicopy genes. Science 2010,
330:641–646.
49. McCarroll SA, Altshuler DM: Copy-number variation and association
studies of human disease. Nat Genet 2007, 39:S37–S42.
50. Team RDC: R: A Language and Environment for Statistical Computing. Vienna:
R Foundation for Statistical Computing; 2010.
51. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ,
Salzberg SL, Wold BJ, Pachter L: Transcript assembly and quantification by
RNA-Seq reveals unannotated transcripts and isoform switching during
cell differentiation. Nat Biotechnol 2010, 28:511–515.
52. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Mehdi SQ, Kajuna SLB,
Barta C, Kungulilo S, Karoma NJ, Lu R-B, Zhukova OV, Kim J-J, Comas D,
Siniscalco M, New M, Li P, Li H, Manolopoulos VG, Speed WC, Rajeevan H,
Pakstis AJ, Kidd JR, Kidd KK: The distribution and most recent common
ancestor of the 17q21 inversion in humans. Am J Hum Genet 2010,
86:161–171.
doi:10.1186/1756-8935-5-6
Cite this article as: Prendergast et al.: A genome-wide screen in human
embryonic stem cells reveals novel sites of allele-specific histone
modification associated with known disease loci. Epigenetics & Chromatin
2012 5:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Prendergast et al. Epigenetics & Chromatin 2012, 5:6 Page 13 of 13
http://www.epigeneticsandchromatin.com/content/5/1/6
